[go: up one dir, main page]

AU2003213168A8 - Immunogenic hbc chimer particles stabilized with an n-terminal cysteine - Google Patents

Immunogenic hbc chimer particles stabilized with an n-terminal cysteine

Info

Publication number
AU2003213168A8
AU2003213168A8 AU2003213168A AU2003213168A AU2003213168A8 AU 2003213168 A8 AU2003213168 A8 AU 2003213168A8 AU 2003213168 A AU2003213168 A AU 2003213168A AU 2003213168 A AU2003213168 A AU 2003213168A AU 2003213168 A8 AU2003213168 A8 AU 2003213168A8
Authority
AU
Australia
Prior art keywords
terminal cysteine
particles stabilized
hbc chimer
chimer particles
immunogenic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003213168A
Other versions
AU2003213168A1 (en
Inventor
Ashley J Birkett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apovia Inc
Original Assignee
Apovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/080,299 external-priority patent/US20030175863A1/en
Priority claimed from US10/082,014 external-priority patent/US20030185858A1/en
Priority claimed from US10/274,616 external-priority patent/US20030202982A1/en
Application filed by Apovia Inc filed Critical Apovia Inc
Publication of AU2003213168A1 publication Critical patent/AU2003213168A1/en
Publication of AU2003213168A8 publication Critical patent/AU2003213168A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003213168A 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE Abandoned AU2003213168A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US10/080,299 US20030175863A1 (en) 2001-08-15 2002-02-21 Influenza immunogen and vaccine
US10/080,299 2002-02-21
US10/082,014 2002-02-21
US10/082,014 US20030185858A1 (en) 2001-08-15 2002-02-21 Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US10/274,616 US20030202982A1 (en) 2001-08-15 2002-10-21 Influenza immunogen and vaccine
US10/274,616 2002-10-21
PCT/US2003/005196 WO2003102165A2 (en) 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Publications (2)

Publication Number Publication Date
AU2003213168A1 AU2003213168A1 (en) 2003-12-19
AU2003213168A8 true AU2003213168A8 (en) 2003-12-19

Family

ID=29715970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003213168A Abandoned AU2003213168A1 (en) 2002-02-21 2003-02-21 IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE

Country Status (3)

Country Link
EP (1) EP1517702A4 (en)
AU (1) AU2003213168A1 (en)
WO (1) WO2003102165A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis
AU2007224034B2 (en) 2006-03-07 2012-03-29 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
JP2009543554A (en) 2006-07-14 2009-12-10 サノフィ パスツール バイオロジクス カンパニー Construction of recombinant viral vaccines by direct transposon-mediated insertion of foreign immune determinants into vector viral proteins
AU2007347184A1 (en) 2006-09-29 2008-08-21 Sanofi Pasteur Biologics Co Recombinant rhinovirus vectors
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
WO2009128949A2 (en) 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
DK2376108T3 (en) 2008-12-09 2017-04-24 Pfizer Vaccines Llc IgE CH3 peptide vaccine
PE20120817A1 (en) 2009-07-30 2012-07-07 Pfizer Vaccines Llc ANTIGENIC TAU PEPTIDES AND USES OF THEM
TR201808222T4 (en) 2009-09-03 2018-07-23 Pfizer Vaccines Llc PCSK9 vaccine.
EP2942061A3 (en) 2010-06-07 2016-01-13 Pfizer Vaccines LLC Ige ch3 peptide vaccine
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
CN106279379B (en) * 2016-09-13 2020-05-22 华兰生物工程股份有限公司 Immunogen HM4-M2e, and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143726A (en) * 1986-12-09 1992-09-01 The Scripps Research Institute T cell epitopes of the hepatitis B virus nucleocapsid protein
EP1054689B1 (en) * 1998-02-12 2003-09-10 Immune Complex, Corporation Strategically modified hepatitis b core proteins and their derivatives
US5990085A (en) * 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability

Also Published As

Publication number Publication date
WO2003102165A2 (en) 2003-12-11
AU2003213168A1 (en) 2003-12-19
WO2003102165A3 (en) 2005-01-06
EP1517702A2 (en) 2005-03-30
EP1517702A4 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
EP1492049A4 (en) Face meta-data creation
HRP20041200A2 (en) Acidic insulin preparations with improved stability
IL172059A0 (en) Stabilized radiopharmaceutical compositions and methods for the preparation thereof
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
EP1578930A4 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
SG106158A1 (en) Screw-on for timepiece
PL377591A1 (en) Stabilized exendin-4 compounds
GB2419421B (en) Gas flow standard
GB2392424B (en) Fuel sender assembly
AU2003213168A8 (en) Immunogenic hbc chimer particles stabilized with an n-terminal cysteine
IL176385A0 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
AU2003206862A1 (en) Hepatitis b vaccines
GB0310395D0 (en) Fuel sender assembly
AU2003215395A8 (en) Stabilized hbc chimer particles having meningoccocal immunogens
IL168106A0 (en) Stabilized, solid-state polypeptide particles
TW547897U (en) Housing with separated carrying seat
EP1558628A4 (en) Antigenic peptides
AU2003303222A8 (en) Mutant proteins with increased secretion
EP1539792A4 (en) Cngh0005 polypeptides, antibodies, compositions, methods and uses
GB0223696D0 (en) Improved immunotherapy
AU2003249282A1 (en) Glanders/meliodosis vaccines
AU2003228863A8 (en) Immunogenic peptides
GB0201382D0 (en) Virus-like particles
GB0218977D0 (en) Polypeptide
PL372202A1 (en) Modified byrodin 1 with reduced immunogenicity

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase